Korean J Urol Oncol.  2019 Apr;17(1):22-33. 10.22465/kjuo.2019.17.1.22.

The Treatments for Intermediate Risk Prostate Cancer

  • 1Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
  • 2Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • 3Department of Urology, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • 4Department of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • 5Department of Urology, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
  • 6Department of Urology, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea. yeoluvk@gmail.com


The population of intermediate-risk prostate cancer patients is a large heterogeneous group with diverse prognoses and challenges the struggle to develop more meticulous and standardized treatment recommendations. Furthermore, there are no specific treatment guidelines based on Korean patients although the cancer nature of this patient group is known to be somewhat different from those of western patients. This review will examine the treatment options for intermediate-risk prostate cancer patients in specific clinical situations. The literature provides evidence that combining androgen deprivation therapy (ADT) for 6 months with radiation therapy (RT) may have superior survival than RT alone. Also, patients with adverse pathologic features and lymph node metastasis will benefit from adjuvant RT and ADT respectively after radical prostatectomy (RP). In addition, patients with life expectancy ≥10 years will benefit from lymphadenectomy during RP when lymph node metastasis is suspected as well as neurovascular bundle saving during RP is recommended because of its superior functional results.


Prostatic neoplasms; Prostatectomy; Radiotherapy; Antineoplastic agents

MeSH Terms

Antineoplastic Agents
Life Expectancy
Lymph Node Excision
Lymph Nodes
Neoplasm Metastasis
Prostatic Neoplasms*
Antineoplastic Agents
Full Text Links
  • KJUO
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr